Worldwide Clinical Trials and Deep Lens Enter Strategic Alliance to Accelerate Recruitment and Development Timelines for Oncology Trials

MORRISVILLE, N.C. & COLUMBUS, Ohio–(BUSINESS WIRE)–Worldwide
Clinical Trials, Inc.
(Worldwide), an award-winning, full-service,
midsize, global CRO, and Deep
Lens
, an AI-driven digital pathology company focused on disease
diagnosis confirmation and clinical trial recruitment, today announced a
new strategic alliance in oncology. The companies will pair Worldwide’s
expertise in clinical cancer research and global clinical trial
operations with the Deep Lens VIPER™ digital pathology platform. This
combination will support a new ecosystem for sponsors, researchers and
care teams to accelerate cancer diagnoses and present clearer treatment
and clinical trial options earlier in the process.


Patient recruitment for clinical trials remains a time-intensive, costly
barrier to the execution of drug development programs. More than 14,000
oncology clinical trials are actively recruiting patientsi,
yet estimates put the rate of participation as low as 3 percent of
potential trial candidates.ii Worldwide and Deep Lens will
address this challenge by first collaborating to design a pilot study to
marry innovative clinical trial designs and operational acumen with the
VIPER platform. The aim is to enhance trial recruitment through
real-time diagnosis and alerting and enhance coordination between
research teams, care teams and patients.

“Cancer research is advancing at an incredible pace. We need to up our
game as pathologists and CROs to deliver increased precision, speed and
communication to find patients with particular disease subtypes or
biomarkers,” said Dave Billiter, co-founder and CEO, Deep Lens. “With
the global reach and scientific and operations expertise of Worldwide,
we believe we can streamline clinical trial recruitment. And, just as
importantly, oncologists can inform patients and their caregivers about
clinical research options from day one.”

Through the strategic alliance, Worldwide and Deep Lens seek to:

  • Accelerate oncology patient recruitment for clinical trials
  • Advance clinical research as a care option (CRAACO) where the critical
    conversation with a patient is enabled at the point in their journey
    that is most impactful
  • Create trusted networks of precision diagnosis and clinical research
    options
  • Provide biopharmaceutical clients with a new platform for basket and
    umbrella study designs that can quickly process diagnosis and tumor
    response in real time
  • Support pre-competitive research into better clinical trial approaches
    by organizing “data clubs” (disease-specific consortia) of industry
    stakeholders

“Worldwide and Deep Lens are collaborating to drive critical, lifesaving
decisions earlier in the treatment conversation – where days can impact
outcomes. For sponsors, this further builds on our commitment to provide
uncommon scientific and operational expertise throughout the clinical
research process,” said Dave Bowser, executive vice president and
general manager, Worldwide Clinical Trials. “For patients, the alliance
seeks to bring clarity and confidence to the incredibly challenging
moment they are diagnosed with cancer.”

With operations spanning 60 countries, Worldwide offers biopharma
sponsors the clinical, technical and regulatory expertise they need to
navigate the international and strategic complexities of oncology drug
development – including proven ability to access hard-to-find patient
populations.

Deep Lens offers a modernized, AI-driven approach to pathology.

Together, the companies will address unique barriers to recruitment.
These include:

  • Deployment of advances in digital pathology, deep learning and
    workflow for interventional and observational research in oncology;
  • Accelerated characterization of complex oncology sub-types and stages
    in real time; and
  • Engaging study teams and care teams in meaningful patient
    conversations about treatment options.

By working with Deep Lens on clinical trial recruitment, Worldwide can
reach upstream from the oncologist to the pathologist, enabling
identification of eligible patients at the time of their diagnosis –
much sooner than current methods. Going straight to the source can
fast-track trial enrollment and potentially shorten the duration of the
trial.

About Worldwide Clinical Trials

Worldwide Clinical Trials employs more than 1,600 professionals around
the world, with offices in North and South America, Eastern and Western
Europe, Russia, and Asia. Founded by physicians committed to advancing
medical science, Worldwide is out to change how the world experiences
CROs – in the best possible way. From early phase and bioanalytical
sciences through late phase, post-approval and real-world evidence, we
provide world-class, full-service drug development services.

With infrastructure and talent spanning 60 countries, we execute
predictable, successful studies with operational excellence across a
range of therapeutic areas, including central nervous system,
cardiovascular, metabolic, immune-mediated inflammatory disorders
(IMID), oncology and rare diseases. We never compromise on science or
safety. We’re never satisfied with the status quo. We’re the Cure for
the Common CRO.

For more information, visit http://www.worldwide.com.

About Deep Lens

Deep Lens has extended one of the world’s first digital pathology cloud
platforms, VIPER, to include artificial intelligence, enhanced pathology
workflow support and collaboration capabilities. In addition to
providing essential workflow support to pathology teams, Deep Lens
offers the most precise and timely source for identifying sites and
patients for sponsored clinical trials.

For more information, visit https://www.deeplens.ai/.

ihttps://clinicaltrials.gov,
Last accessed February 28, 2019
iihttps://www.ncbi.nlm.nih.gov/books/NBK50895/

Contacts

Worldwide Clinical Trials:
Sherri Stuart, Vice President,
Global Marketing and Communications
Sherri.Stuart@worldwide.com

Deep Lens:
Jessica Yingling, Ph.D., President, Little Dog
Communications Inc.
jessica@litldog.com

error: Content is protected !!